Related Experiment Video
Updated: Jun 4, 2026
Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques
Published on: July 5, 2018
The double-edged nature of antibody bivalency: mathematical and experimental analysis of cell surface antigen
Luke Heirene1, James Lodge2,3, Marina Fedorova2
1Mathematical Institute, University of Oxford, Oxford, United Kingdom.
Monoclonal antibodies are bivalent molecules and are thus able to engage two antigens concurrently, a property termed avidity. The therapeutic efficacy of an antibody drug can be broadly defined as a consequence of either antigen occupancy or target cell opsonization. Therefore, depending on the intended mechanism of action, avid engagement of a therapeutic antibody may be desirable in order to attain high antigen occupancy and consequent antagonism. In some cases, such as target cell opsonization and Fc-mediated cytotoxicity, avidity may limit efficacy when antigens are occupied with fewer antibodies per cell. In this study, we utilized a mathematical model of antibody-antigen binding to identify conditions under which avidity hinders or enhances therapeutic potential. We calibrated the model with in vitro assays exploring the binding of a bivalent and monovalent panel of anti-PD-1 antibodies with a range of affinities, against cell lines with a range of target densities. In calibrating the model to the in vitro binding data, we observed an affinity-dependent discrepancy between experimentally observed and model-predicted cell binding that we hypothesize arises due to unavoidable assay limitations. The calibrated model was then reused to correct for the assay bias and to generate refined estimates for on-cell antibody binding. The predictions generated by this model for the influence of avidity on cell surface receptor engagement with therapeutic antibodies may guide strategies for their structural engineering and dosing.
Monoclonal antibodies are bivalent molecules and are thus able to engage two antigens concurrently, a property termed avidity. The therapeutic efficacy of an antibody drug can be broadly defined as a consequence of either antigen occupancy or target cell opsonization. Therefore, depending on the intended mechanism of action, avid engagement of a therapeutic antibody may be desirable in order to attain high antigen occupancy and consequent antagonism. In some cases, such as target cell opsonization and Fc-mediated cytotoxicity, avidity may limit efficacy when antigens are occupied with fewer antibodies per cell. In this study, we utilized a mathematical model of antibody-antigen binding to identify conditions under which avidity hinders or enhances therapeutic potential. We calibrated the model with in vitro assays exploring the binding of a bivalent and monovalent panel of anti-PD-1 antibodies with a range of affinities, against cell lines with a range of target densities. In calibrating the model to the in vitro binding data, we observed an affinity-dependent discrepancy between experimentally observed and model-predicted cell binding that we hypothesize arises due to unavoidable assay limitations. The calibrated model was then reused to correct for the assay bias and to generate refined estimates for on-cell antibody binding. The predictions generated by this model for the influence of avidity on cell surface receptor engagement with therapeutic antibodies may guide strategies for their structural engineering and dosing.
Related Concept Videos
01:41Affinity and Avidity
01:26Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
01:10Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
01:10Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
01:25Antibody Structure and Classes
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
01:24B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...